Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke
Publikováno v:
Clinical Cancer Research. 28:677-688
Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN genes (STING) pathway, in patients with advanced/metastatic cancers
Autor:
Adam Zong, Lixin Li, Anthony W. Tolcher, Melissa Lynne Johnson, Robert H.I. Andtbacka, Manish R. Patel, Alexander Chung, Drew W. Rasco
Publikováno v:
Regular and young investigator award abstracts.
Background TLR agonists mediate antitumor activity through dendritic cell (DC) activation. Most TLR agonists in development are administered intratumorally allowing for less than 30% of advanced solid tumor to be treated. BDB001 is an intravenously a
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Merrick I. Ross, Howard L. Kaufman, Keith A. Delman, Frances A. Collichio, Mohammed M. Milhem, Thomas Amatruda, Jonathan S. Zager, Lisa Chen, Igor Puzanov, Mark Shilkrut, Robert H.I. Andtbacka, Lee D. Cranmer, Eddy C. Hsueh
Publikováno v:
Annals of Surgical Oncology
Purpose Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we
Autor:
Leena P. Bharath, Van Reese, Jayson R. Gifford, Stephen J. Ives, Song-Young Park, John R. Hyngstrom, Robert H.I. Andtbacka, John D. Symons, Russell S. Richardson, Gwenael Layec
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 310:H217-H225
Although advancing age is often associated with attenuated skeletal muscle blood flow and skeletal muscle feed arteries (SMFAs) have been recognized to play a regulatory role in the vasculature, little is known about the impact of age on the vasodila
Autor:
Lisa A. Lesniewski, Anthony J. Donato, Robert H.I. Andtbacka, R. Dirk Noyes, Stephen J. Ives, Richard M. Cawthon, Russell S. Richardson, Richard G. Morgan
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 305:H251-H258
Arterial telomere dysfunction may contribute to chronic arterial inflammation by inducing cellular senescence and subsequent senescence-associated inflammation. Although telomere shortening has been associated with arterial aging in humans, age-relat
Autor:
Jayson R. Gifford, Robert H.I. Andtbacka, Russell S. Richardson, Stephen J. Ives, J. David Symons, R. Dirk Noyes, Song-Young Park, R. Garrett Morgan
Publikováno v:
Experimental Physiology. 98:256-267
Graded exercise results not only in the modulation of adrenergic mediated smooth muscle tone and a preferential increase in blood flow to the active skeletal muscle termed 'functional sympatholysis', but is also paralleled by metabolically induced re
Autor:
Robert H.I. Andtbacka, Song-Young Park, R. D. Noyes, Jayson R. Gifford, Lisa A. Lesniewski, Russell S. Richardson, Stephen J. Ives, Anthony J. Donato
Publikováno v:
Acta Physiologica. 206:135-141
Aim: Recently, it has been recognized that human skeletal muscle feedarteries can be harvested during exploratory surgery for melanoma. Thisapproach provides vessels for in vitro study from a wide spectrum of rela-tively healthy humans. Although, the
Autor:
R. Dirk Noyes, J. David Symons, John McDaniel, Markus Amann, D. Walter Wray, Robert H.I. Andtbacka, Russell S. Richardson, Melissa A. H. Witman, Stephen J. Ives
Publikováno v:
Experimental Physiology. 96:907-918
Heat and cold exposure can decrease and increase total peripheral resistance, respectively, in humans. With unique access to human skeletal muscle feed arteries, we sought both to characterize these vessels and to determine the interaction between te
Autor:
Neil Senzer, Igor Puzanov, Bin Yao, Gerald P. Linette, Lynn E. Spitler, Sanjiv S. Agarwala, Susan Doleman, Troy H. Guthrie, Jason Chesney, Ari M. Vanderwalde, Robert Coffin, Keith A. Delman, Lee D. Cranmer, Kevin J. Harrington, Karl D. Lewis, Gregory A. Daniels, Jennifer Gansert, Jonathan S. Zager, Merrick I. Ross, Brendan D. Curti, Ai Li, Mark R. Middleton, Howard L. Kaufman, Wilson H. Miller, Mohammed M. Milhem, Thomas Amatruda, Yining Ye, Frances A. Collichio, Robert H.I. Andtbacka
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(25)
Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic anti